SCHEMBL8722156

SCHEMBL8722156

CCCC(=O)c1ccccc1C(=O)Nc1ccc2scc(C3CCC4CCCCN4CC3)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.38
SLC6A4 P31645 1/20 0.38
HTR7 P34969 1/20 0.38
L3MBTL3 Q96JM7 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TDP1 Q9NUW8 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
RORC P51449 1/20 0.35
OPRM1 P35372 2/20 0.35
OPRK1 P41145 2/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
P2RY12 Q9H244 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
MAOB P27338 1/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30909070 0.91 TDP1 (0.38) L3MBTL3L3MBTL1TDP1HRH3RORC
SCHEMBL8721187 0.91 TDP1 (0.38) L3MBTL3L3MBTL1TDP1HRH3RORC
SCHEMBL8720655 0.88 PNLIP (0.41) DRD2SLC6A4
SCHEMBL30909140 0.88 PNLIP (0.41) DRD2SLC6A4
SCHEMBL8723596 0.87 ALDH1A1 (0.44) L3MBTL1TDP1CYP2D6CYP3A4CYP2C19
SCHEMBL30908934 0.87 ALDH1A1 (0.44) L3MBTL1TDP1CYP2D6CYP3A4CYP2C19
SCHEMBL8722104 0.86 HCRTR1 (0.39) DRD2SLC6A4HRH3OPRK1
SCHEMBL30909087 0.86 HCRTR1 (0.39) DRD2SLC6A4HRH3OPRK1
SCHEMBL8725928 0.85 RORC (0.47) L3MBTL3L3MBTL1TDP1HRH3RORC
SCHEMBL8720774 0.83 L3MBTL3 (0.43) DRD2L3MBTL3L3MBTL1HRH3RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D DRD2 691/4885SLC6A4 299/4885HTR7 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.